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Background: Reports of recurrence following restructuring of primary giant cell tumor (GCT) defects using
polymethyl methacrylate (PMMA) bone cementation or allogeneic bone graft with and without adjuvants for
intralesional curettage vary widely. Systematic review and meta-analysis were conducted to investigate efficacy of
PMMA bone cementation and allogeneic bone grafting following intralesional curettage for GCT.
Methods: Medline, EMBASE, Google Scholar, and Cochrane databases were searched for studies reporting GCT of
bone treatment with PMMA cementation and/or bone grafting with or without adjuvant therapy following
intralesional curettage of primary GCTs. Pooled risk ratios and 95% confidence intervals (CIs) for local recurrence
risks were calculated by fixed-effects methods.
Results: Of 1,690 relevant titles, 6 eligible studies (1,293 patients) spanning March 2008 to December 2011 were
identified in published data. Treatment outcomes of PMMA-only (n = 374), bone graft-only (n = 436), PMMA with or
without adjuvant (PMMA + adjuvant; n = 594), and bone graft filling with or without adjuvant (bone graft + adjuvant;
n = 699) were compared. Bone graft-only patients exhibited higher recurrence rates than PMMA-treated patients
(RR 2.09, 95% CI (1.64, 2.66), Overall effect: Z = 6.00; P <0.001), and bone graft + adjuvant patients exhibited higher
recurrence rates than PMMA + adjuvant patients (RR 1.66, 95% CI (1.21, 2.28), Overall effect: Z = 3.15, P = 0.002).
Conclusions: Local recurrence was minimal in PMMA cementation patients, suggesting that PMMA is preferable for
routine clinical restructuring in eligible GCT patients. Relationships between tumor characteristics, other modern
adjuvants, and recurrence require further exploration.
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Giant cell tumors (GCTs) of bone are primary bone
tumors of mesenchymal origin that commonly present as
localized osteolytic lesions in the epiphysiometaphyseal
region of long bones, though these tumors also occur
with relatively lower frequency in other bone monostotic
processes [1]. GCTs account for up to 20% of all primary* Correspondence: yingqi.hua@yahoo.com; zhdcai@126.com
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reproduction in any medium, provided the orskeletal neoplasms [1] and 5% of all adult primary bone
tumors [2]. Recurrence reports in patient subpopulations
vary, ranging from 0% to 65% [2].
For benign to locally aggressive GCT tumors, recurrence
is most common in local tissues due to narrow surgical
margins [3]; however, 3.5% of GCT patients develop remote
benign or metastatic lesions [4-6], with malignancy variably
reported in ≤30% of cases [7]. Diverse presentations,
diagnostic methods, and treatment methodologies
may contribute to discrepancies between reports [7,8].
Since the relatively recent decline of affected limb. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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course and proper treatment selection have become more
challenging [9]. Though modern curettage with local
adjuvant or en bloc excision with prosthetic reconstruction
are widely accepted treatment strategies for GCT of bone,
consistently reported to reduce recurrence compared to
wide excision [10-17], there is no consensus for optimal
surgical curettage methodology, including fillers and
adjuvants, to limit recurrence.
In routine intralesional curettage for GCTs of bone,
adjuvants, such as the thermal adjuvant polymethyl meth-
acrylate (PMMA) and chemical adjuvant phenol, have
been recommended to reduce local recurrence following
intralesional surgery, resulting in disease-free survival
rates as high as 85% [2]. PMMA cementation treatment
after curettage immediately stabilizes the affected limb
and releases heat during polymerization that may kill
remaining tumor cells [18,19], achieving recurrence rates
ranging from 12 to 65.2% in various reports [13,20].
For lesions near the articulating surface, subchondral
allogeneic bone grafting is also a widely accepted alternative
for filling voids during intralesional curettage either
with or without additional adjuvants, with recurrence
rates comparable to PMMA treatment [2].
Despite the prevalence of studies concerning GCT and
its recurrence, little conclusive data and no widely accepted
consensus for optimal surgical management and adjuvant
selection for GCT of bone are available. The current study
investigates the efficacy of PMMA bone cementation and
allogeneic bone grafting following intralesional curettage
for surgical management of GCT of bone through a
systematic review and meta-analysis, thus providing
evidence for clinical treatment selection.
Methods
Study design
A systematic literature search was performed to identify
cohort studies assessing efficacy and recurrence of
primary GCT following intralesional curettage treatment
with only PMMA bone cementation (PMMA-only), only
allogeneic bone grafting (bone graft-only), PMMA bone
cementation with or without adjuvant (PPMA + adjuvant),
and allogeneic bone grafting with or without adjuvant
(bone graft + adjuvant). Results were systematically
analyzed to determine the relationship between treatment
methods and recurrence rates in PMMA-treated and bone
graft-treated patients.
Inclusion and exclusion criteria
Studies were included that reported information pertaining
to efficacy and recurrence of GCT of bone following
treatment with PMMA bone cementation or allogeneic
bone grafting with or without other adjuvants. All included
studies (1) contained patients who underwent intralesionalcurettage for treatment of pathologically verified primary
GCTs; (2) reported void filling with either PMMA or
allogeneic bone graft; (3) reported recurrence rates
following intralesional curettage with ≥2 treatment
groups for efficacy assessments; and (4) reported a ≥3
year follow-up period. All included studies were also
(5) published or previously translated into in the English
language. Studies that (1) did not include a retrospective
control group or (2) contained patient cohorts sized ≤30
patients for any group were excluded.
Database search terms
Electronic searches were performed using the elec-
tronic databases provided by Google Scholar (1966 to
September 2012), Medline (1966 to September 2012),
EMBASE (1974 to September 2012), and the Cochrane
Controlled Trial Register (Cochrane library 2012). Two
independent researchers conducted literature searches
using the search keywords ‘bone cement’, ‘PMMA’,
‘polymethyl methacrylate’, ‘bone graft’, ‘giant cell tumor
of bone’, and ‘recurrence’ with various combinations
of the operators ‘AND’, ‘NOT’, and ‘OR’.
Quality assessment
Eligible studies were evaluated for inclusion by two
independent reviewers (Zuo and Hua), and the level
of agreement between reviewers was recorded. Inclusion
of resultant titles was determined by screening of manual
titles and abstracts, followed by full-text screening by the
same reviewers. The quality of each study was assessed
using the Methodological Index for Nonrandomized
Studies (MINORs) scoring system [21] and the Newcastle
Ottawa Quality Assessment Scale (NOQAS). These scales
were used to allocate a maximum of nine points for quality
of selection, comparability, exposure, and outcome of study
participants. In the event of incomplete data, authors
of potentially eligible studies were contacted to obtain
relevant unpublished data.
Outcome measurement
Local recurrence was the primary endpoint for analysis.
Recurrence was defined as radiological and pathological
evidence of local disease recurrence necessitating further
surgical intervention.
Statistical analysis
All data were analyzed using RevMan v.5.1 software
(Cochrane Collaboration, Copenhagen, Denmark). Risk
ratio (RR) and 95% confidence intervals (CIs) were reported.
Heterogeneity among studies was assessed using Cochrane’s
Q test with a P value equal to 0.1. An I-squared (variability)
statistic is the percentage of total variation across studies
due to heterogeneity. A random effects model was
used for heterogeneous data; otherwise, a fixed effect
Zuo et al. World Journal of Surgical Oncology 2013, 11:156 Page 3 of 7
http://www.wjso.com/content/11/1/156model was used. Meta-analysis of pooled risk ratios
was performed. P values less than 0.05 were considered
statistically significant (P <0.05).Result
Literature search
Initial electronic database searches yielded 1,690 relevant
titles, of which 1,671 were excluded due to failure to
meet the inclusion criteria. The remaining 19 articles
were subjected to full-text review, resulting in exclusion of
8 additional articles due to failure to meet the inclusion
criteria, most commonly due to inappropriate comparison
methods. Additionally, two articles [10,17] were excluded
due to insufficient primary GCT data. Notably, in both
cases, original data was not able to be obtained from the
corresponding authors. Furthermore, although three studies
[22-24] included in the meta-analysis conducted by
Liu et al. [25] met the inclusion criteria, these studies
were excluded due to the relatively small number of
included cases (35 PMMA-only and 20 bone graft-only).
Study inclusion is detailed in Figure 1. Systematic review
and meta-analysis were conducted using the remaining six
included studies [2,11,12,14,15,20].Study characteristics and quality assessment
In these 6 included retrospective cohort studies, data
were reported for a total of 1,293 patients with primary
GCTs of bone treated with either intralesional curettage
or other resection methodologies. Median follow-up times
for each study ranged from 60 to 108 months. Publication
dates ranged from March 2008 to December 2011. Quality
assessments revealed average NOQAS scores from
the two reviewers of 7.4 and 7.0, indicating that all
six included studies were of moderate quality.Figure 1 Flow diagram detailing study inclusion.PMMA treatment was administered to 594 patients,
and the remaining 699 patients underwent no PMMA
treatment. Among the total 1,293 patients, 436 patients
were treated only with intralesional curettage and bone
graft, and 373 patients were treated only with intralesional
curettage and PMMA cementation. Patient demographics,
follow-up, and lesion characteristics are detailed in Table 1.
Heterogeneity of studies
Variability (I-squared) in the results of the four studies
used to compare PMMA-only and bone graft-only patients
demonstrated a true difference in treatment effect of 0%,
indicating no heterogeneity. In all six studies used to
compare PPMA + adjuvant and bone graft + adjuvant
patients, I-squared values were 56%, indicating relatively
high heterogeneity. Thus, a random effects model was
employed to adjust for heterogeneity prior to comparison
of PPMA + adjuvant and bone graft + adjuvant patients.
Local recurrence
Complete data for recurrence was available in all included
studies, and all six studies were included in analysis of local
recurrence. Local recurrence rates differed significantly
between PMMA-only patients and bone graft-only patients,
with bone graft-only patients exhibiting significantly higher
recurrence rates than PMMA-only patients (RR = 2.09,
95% CI (1.64, 2.66), Overall effect: Z = 6.00; P <0.001;
Figure 2). Local recurrence rates also differed between
PPMA + adjuvant patients and bone graft + adjuvant
patients. Bone graft + adjuvant patients also demonstrated
higher levels of recurrence compared to PPMA + adjuvant
patients (RR = 1.87, 95% CI (1.55, 3.55), Test for overall
effect: Z = 6.25; P <0.001; Figure 3).
Discussion and conclusions
In order to provide an accurate and contemporary analysis
of GCT of bone treatments, the current meta-analysis
was conducted of six methodologically sound studies,
encompassing 1,293 GCT patients. Included patients
were treated with intralesional curettage followed by
PMMA cementation or allogeneic bone grafting, with
results clearly indicating that PMMA cementation more
optimally reduces recurrence risk in these patients. Despite
extensive recent investigations of the relationships between
adjuvant use and treatment efficacy, recurrence, and GCT
of bone aggression, no consensus for proper treatment has
been widely accepted. Thus, the current study provides
novel and compelling evidence supporting preferential
use of PMMA cementation in contemporary clinical
intralesional curettage for GCT of bone.
No wide consensus has been reached for preferential
use of PMMA or bone graft treatments in GCT of bone,
with conflicting recent evidence attributable primarily
to methodological discrepancies between studies. In a
Table 1 The details of the six articles included in the current review and a meta-analysis
Study Publication date Follow-up Patient
no.




Becker et al. [20] 2008 63 384 Total cohort
78/384 wide resection 2.00% 1
103/384 curettage (bone graft) 49.00% 56
102/384 curettage + PMMA 22.00% 23
74/384 curettage + PMMA + phenol 27.00% 20
27/384 curettage + toxic(bone graft) 15.00% 4
Errani et al. [11] 2010 91 349 Total cohort
149/349 wide resection 12.00% 18
136/349 Curettage + burr + phenol 17.60% 24
64/349 Curettage + burr + phenol + PMMA 12.50% 8
Kivioja et al. [15] 2008 60 months 294 Total cohort
92/294 wide resection 12.00% 11
47/294 curettage 51.00% 24
147/294 curettage + PMMA 22.00% 32
Klenke et al. [2] 2010 108 months 118 Total cohort
UN wide resection 5.00% unknown
22/118 curettage + burr 32.00% 7
32/118 curettage + burr + phenol 34.00% 11
41/118 curettage + burr + phenol + PMMA 15.00% 6
Gaston et al. [12] 2011 76.5 months 330 Total cohort
246/330 curettage 28.70% 67
84/330 curettage + PMMA 14.30% 12
Jamshidi et al. [14] 2008 74 months 168 Total cohort
40/168 curettage + bone 42.50% 17
40/168 curettage + cement 30.00% 12
46/168 curettage + burr + bone 21.70% 10
42/168 curettage + burr + cement 16.70% 7
Harness et al. [22] 2004 72 months 31
5/31 curettage + bone 40.00% 2
26/31 curettage + PMMA 42.00% 11
Ozalp et al. [23] 2006 80 months 8 Total cohort
6/8 curettage + bone 50.00% 3
2/8 curettage + PMMA 50.00% 1
Sheth et al. [24] 1995 108 months 16 Total cohort
9/16 curettage + bone 33.00% 3
7/16 curettage + PMMA 28.50% 2
Zuo et al. World Journal of Surgical Oncology 2013, 11:156 Page 4 of 7
http://www.wjso.com/content/11/1/156multicenter retrospective study of sarcoma in 294
Scandinavian patients at 13 centers followed for a
median of 5 years, Kivioja et al. [15] reported that PMMA
cementation significantly reduced local recurrence rates
following intralesional curettage, supporting widespread
preferential use of PMMA treatments. Similar results were
reported in a 384-patient, multicenter study conducted byBecker et al. [20], wherein 22% of GCT patients treated
with PMMA and 49% of GCT patients treated with bone
graft exhibited local recurrence within 63 months, evi-
dence that further supports the use of PMMA treatments.
Conversely, Liu et al. [25] conducted a systematic review
and meta-analysis of 80 intralesional curettage patients
with GCT of the distal radius, reporting that PMMA
Figure 2 Forest plot for recurrence comparison between patients with intralesional curettage followed by polymethyl methacrylate
(PMMA) cementation alone (PMMA-only) or bone grafting (bone graft-only).
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bone graft, with PMMA treatments exhibiting both higher
rates of local recurrence and metastatic events. These dis-
crepancies may be due to methodological differences as
well as the fast-paced changes in routine surgical practices
over the last several decades, indicating that contemporary
evaluation of these methods is required. Thus, a consensus
pertaining to treatment standards for GCT has not yet been
reached, though the current study provides powerful,
contemporary evidence to support preferential PMMA
adjuvant use in modern clinical settings.
Without the use of adjuvants, reoccurrence rates
following intralesional curettage as high as 35 to 49%
have been reported [2,20]. Increases in available adjuvant
types and numbers in recent years have, however, further
complicated the treatment selection process for GCT
patients, though few studies have conducted systematic
comparisons of the cytotoxic characteristics of specific
adjuvant formulations [26]. As a result, the vast selection
of clinically-approved adjuvants may be overwhelming
for many clinicians, resulting in default use of sub-
optimal older methods due to subjective comfort levels
rather than clinical viability [26]. Several reports have
reported dramatic decreases in recurrence rates in
patients treated with PMMA, PMMA with phenol, or
phenol with other chemical adjuvants (22%, 27%, and
15% recurrence, respectively) [3,16,27,28]. Niu et al. [16]
reported that extended curettage with combined high speed
burring, bone graft, and PMMA cementation resulted in an
extremely low recurrence rate of 3.3%, though numerous
other studies refute these findings and provide conflicting
results [14,17,25,29,30]. Algawahmed et al. [29] conducted
a systematic review and meta-analysis of 387 GCT patients,Figure 3 Forest plot for recurrence comparison between patients wit
cementation following intralesional curettage.demonstrating that meticulous surgical techniques,
including high-speed burring, are paramount to reducing
GCT recurrence rates. Furthermore, these findings and
those of the current study further indicated that local
adjuvants, such as PMMA, were not associated with
recurrence. Similarly, a meta-analysis of 139 GCT patients
with symptoms in the distal radius conducted by Liu et al.
[25] suggested that tumor recurrence in patients treated
with PMMA did not differ significantly from that observed
in patients treated with bone grafting.
In the current meta-analysis, only four articles were
used to assess PMMA-only and bone-graft only treatments
[12,14,15,20], while six articles were used to assess PMMA
and bone grafts applied either with or without other adju-
vants following intralesional curettage [2,11,12,14,15,20].
The current findings used pooled data to reveal significant
differences in both comparison groups, with primary
GCTs patients treated with PMMA cementation following
intralesional curettage exhibiting relatively lower recurrence
rates than patients treated with bone grafts following
intralesional curettage. It has been hypothesized that the
additional heat produced by the exothermic reaction of in
situ PMMA polymerization may contribute to removal of
remaining tumor cells in the curetted cavity of GCT lesions
[15], thereby reducing recurrence. Similarly, it has been
suggested that abnormal mitosis, increased mitotic rate
(>10 mm2), and permeation of vascular channels may
increase tumor aggressiveness and recurrence rates [7],
thereby making adjuvant treatment with PMMA less useful
due to the larger distribution of tumor cells in local tissues.
While these compounding factors may, in part, explain
the controversial findings reported by different studies,
further clinical, radiologic, and histologic investigationh and without treatment with polymethyl methacrylate (PMMA)
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between adjuvant treatments and the myriad of contem-
porary compounding factors. Based on both previous
findings and current experience, it is hypothetically possible
that tumor volume may also influence recurrence of
primary GCTs. Logically, both PMMA cementation and
bone graft treatments are likely to be less effective following
intralesional curettage in cases of very small tumors, which
are more difficult to excise and fill [31]. Because this raises
the likelihood that some tumor cells will elude the hypo-
thetical thermal effects of PMMA, such adjuvant treatment
is likely to be less effective in GCTs with very small
volumes. This volume-effect hypothesis, however, will
require further clinical exploration.
Despite the relatively large number of patients studied,
the limitations of meta-analyses containing only a small
number of studies must be considered. Due to the relative
scarcity of both the disease and relevant, reputable
randomized control trials, other meta-analyses in this field
have also been conducted using very small groups of
articles, including the studies by Algawahmed et al. [29]
and Liu et al. [25]. The largest number of included
patients were contributed by the report of Becker et al.
[20], consisting of 384 patients. These patients included
256 primary GCT cases and 128 recurrent GCT cases.
Notably, failure to distinguish between primary and recur-
rent GCT cases in the Becker et al. study is a potentially
confounding factor in the current study. The difference
between local recurrence rates between primary and
recurrent tumors was found to be negligible in this
study (21.9% versus 23.4%), and the other two studies
that included both primary and recurrent GCT cases
[10,17] were excluded due to significant differences
between primary local recurrence and overall recurrent
rates (33.5% versus 20% and 35% versus 18%, respectively).
Furthermore, adjuvants applied along with PMMA and
bone graft treatments following curettage were not distin-
guished, and future study will be required to assess whether
different adjuvant combinations may alter outcomes.
It is important to note that when only local recurrence
outcomes are assessed, as in the current study, the effects of
potentially important parameters may be overlooked, such
as metastatic rate, abnormal mitoses, and related major
complication rates. Szalay et al. [32] and Gaston et al. [12]
suggested that joint cartilaginous degeneration may occur
following PMMA cementation in joint arthroplasty.
Similarly, Gaston et al. [12] evaluated the rate of joint
replacement for patients with GCTs, revealing that
patients treated with PMMA evidenced significantly
higher rates of joint replacement. While metastasis in
GCTs patients is rare [33,34], up to 3% of metastatic
GCT occurrences are found in pulmonary tissues
[11,35]. Notably, only three studies [2,11,12] included
in the current analysis provided discrepant resultsrelating to metastasis and function. While this data is
obviously insufficient to conduct a current analysis of
these functional results, this provides an interesting
topic for further study.
The current study of pooled data from 1,293 primary
GCTs cases in six studies in contemporary medical
literature, revealed that PMMA cementation following
intralesional curettage produced lower recurrence rates
compared to recurrence rates in patients treated with
bone grafting. Recent advancements in GCT of bone
treatment methodologies have produced numerous
compounding factors that must be considered in order
to achieve better outcomes in these patients, making
modern adjuvant formulations and surgical methodologies
critical aspects of treatment selection. Thus, this study
provides critically needed systematic, evidence-based
evidence indicating that PMMA is a superior treatment
for the majority of GCT of bone cases treated in routine
clinical practice. To better evaluate new and improved
adjuvant treatments, however, additional multicenter
studies with sufficient and comprehensive data regarding
tumor characteristics will be required.
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